Vanderbilt-Ingram Cancer Center

Harold L. (Hal) Moses, M.D., professor of Medicine and Pathology, and professor and Acting Chair of Cancer Biology, and director emeritus of Vanderbilt-Ingram Cancer Center (VICC), has received the 10th Annual American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research. He received the award April 7 during the AACR Annual Meeting [...]

A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment. The study, led by first author Matthew Resnick, M.D., instructor in Urologic Surgery, Vanderbilt University Medical Center, was [...]

Seventeen members of Vanderbilt University’s faculty have been elected fellows of the American Association for the Advancement of Science (AAAS) this year. This is the largest number of Vanderbilt fellows to be elected in a single year. Vanderbilt University now has 80 AAAS fellows among its current and emeritus faculty. Vanderbilt’s fellows are among 702 [...]

Angiosarcoma, a rare, aggressive tumor that arises from cells that line blood vessels, has a mortality rate of around 80 percent. Because of their constant contact with the blood stream, these tumors can spread quickly and freely throughout the body. The INK4a/ARF locus on chromosome 9 – a region that encodes tumor suppressor proteins – [...]

Vanderbilt-Ingram Cancer Center’s gastrointestinal Specialized Program of Research Excellence (SPORE) has been awarded its third round of funding by the National Cancer Institute (NCI). “We decided to roll the dice and propose high-risk, high-reward projects,” said Robert Coffey Jr., M.D., Ingram Professor of Cancer Research, professor of Medicine and Cell and Developmental Biology, and director [...]

A study led by investigators from Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tenn., finds that black men with prostate cancer receive lower quality surgical care than white men. The racial differences persist even when controlling for factors such as the year of surgery, age, comorbidities and insurance status. Daniel Barocas, M.D., MPH, assistant professor of Urologic [...]

A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy – and may offer a way to further refine personalized cancer treatments. The approach, developed by investigators at Vanderbilt-Ingram Cancer Center, shows that erlotinib – a targeted therapy that acts on a growth factor receptor mutated in [...]

Glioma is the most common and lethal type of brain tumor, and now investigators from Vanderbilt-Ingram Cancer Center and three other cancer centers have identified a link between a rare genetic variant and the risk of developing glioma. The variant also appears to improve the odds of survival among glioma patients. Reid Thompson, M.D., William [...]

Vanderbilt-Ingram Cancer Center researchers have identified how one of the genes most commonly mutated in lung cancer may promote such tumors. The investigators found that the protein encoded by this gene, called EPHA3, normally inhibits tumor formation, and that loss or mutation of the gene — as often happens in lung cancer — diminishes this [...]

Two proteins that act in opposing directions – one that promotes cancer and one that suppresses cancer — regulate the same set of genes in prostate cancer, Vanderbilt-Ingram Cancer Center researchers have found. The findings, reported recently in the Journal of Clinical Investigation, point toward potential drug targets and prognostic markers for prostate cancer. “We [...]